Nikofrenon (Nicotine)

Nicotine in the patch acts as an agonist at nicotinic acetylcholine receptors in the brain. This stimulation releases dopamine and other neurotransmitters, which lessen the intensity of withdrawal and craving sensations, allowing a gradual reduction in nicotine dependence while the user works toward quitting.

The specific dose and duration are determined by the prescribing healthcare professional based on the individual’s smoking history, level of dependence, and treatment goals. Common practice involves selecting a patch strength that matches the patient’s baseline nicotine intake and then tapering over weeks.

Safety data for nicotine patches in pregnancy and lactation are limited. Healthcare providers should weigh the potential risks of nicotine exposure against the benefits of quitting smoking. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative cessation strategies with their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nikofrenon offers continuous nicotine delivery over 24 hours, which can provide more stable plasma levels than short‑acting forms such as gum or lozenges. This steady exposure may reduce the frequency of cravings. However, patch therapy may be less suitable for individuals who prefer dose flexibility or who experience skin irritation.

Store the patches at room temperature, below 25 °C, in the original foil pouch. Keep them away from moisture, direct sunlight, and heat sources. Do not expose the patches to temperatures above 30 °C, as this may affect nicotine stability and adhesive performance.

The patch is applied to a clean, dry, hair‑free area of the upper body or upper outer arm. Press firmly for several seconds to ensure good contact. Change the patch according to the prescribed schedule, typically every 24 hours, and rotate the application site to minimize skin irritation.

Serious adverse events include severe skin reactions such as necrosis, allergic responses like swelling or hives, marked hypotension, tachycardia, and episodes of fainting. Users should seek immediate medical attention if they experience any of these symptoms or notice worsening cardiovascular signs.

Nikofrenon is contraindicated in individuals with known hypersensitivity to nicotine or any patch components, recent myocardial infarction, uncontrolled hypertension, or severe cardiovascular disease. It should also be avoided in patients using other nicotine replacement therapies simultaneously without medical supervision.